Neoplasias malignas das glândulas salivares são lesões raras e o mecanismo pelo qual esses tumores progridem ainda não está completamente esclarecido na literatura. A galectina-3 é uma proteína multifuncional expressa em uma grande quantidade de tecidos normais, mas que também tem sido associada à progressão tumoral de neoplasias malignas da tireóide, próstata e neoplasias gástricas. Estudos prévios demonstraram que a galectina-3 está também expressa em algumas neoplasias malignas das glândulas salivares como carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau de malignidade. Recentemente foi sugerido que a superexpressão da galectina-3 controla alterações nos níveis de expressão de alguns reguladores do ciclo celular, dentre eles a ciclina D1. Além disso, outros estudos revelaram que a ciclina D1 é ativada pela -catenina de uma maneira dependente da galectina-3. O objetivo desse trabalho foi comparar a marcação imunoistoquímica nuclear e / ou citoplasmática da galectina-3 no carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau tentando relacioná-la à marcação da -catenina e ciclina D1. Foram realizadas reações de imunoistoquímica para as três proteínas em 15 casos de carcinoma adenóide cístico e em 15 casos de adenocarcinoma polimorfo de baixo grau utilizando-se material parafinado. Para a galectina-3 os carcinomas adenóides císticos apresentaram marcação imunoistoquímica apenas nas células luminais, predominantemente no núcleo. Todos os casos de adenocarcinoma polimorfo de baixo grau revelaram uma marcação predominantemente citoplasmática para essa proteína. Ambos os tumores exibiram intensa marcação citoplasmática e/ou nuclear para a -catenina na maioria dos casos. Não houve imunorreatividade para a ciclina D1 em 14/15 casos de adenocarcinoma polimorfo de baixo grau. Em contraste, os carcinomas adenóides císticos revelaram marcação nuclear específica para a ciclina D1 em 10 de 15 casos estudados em mais de 5% das células neoplásicas e essa marcação estava associada à marcação citoplasmática e nuclear da galectina-3 (p<0,05). Esses resultados sugerem que nos carcinomas adenóides císticos a expressão da galectina-3 pode exercer uma função de proliferação celular e parece estar relacionada à diferenciação celular no adenocarcinoma polimorfo de baixo grau. Além disso, a perda de expressão da galectina-3 no carcinoma adenóide cístico pode estar associada a um comportamento clínico mais agressivo dessa lesão. Embora a -catenina pareça exercer algum papel no mecanismo de carcinogênese dessas duas lesões, ela não parece se ligar à galectina-3 para ativar a ciclina D1. / Salivary gland tumors are uncommon and the mechanism by which malignant tumors progresses is still undefined. In a previous study it was shown that galectin-3 is expressed in malignant salivary gland neoplasms as adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Galectin-3 is a multifunctional protein of a group of galactoside-binding lectins expressed in a variety of normal cells, but also has been implicated in tumor progression of some malignancies as thyroid, prostate and gastric cancers. Recently, it has been suggested that galectin-3 may be an important mediator of the -catenin/Wnt pathway. Moreover, nuclear galectin-3 expression has been implicated in cell proliferation, promoting cyclin D1 activation. Thus, in the present study we aimed to correlate galectin-3 expression, either nuclear or cytoplasmic, with the expression of -catenin (nuclear/cytoplasmic) and cyclin D1 (nuclear) in 15 cases of adenoid cystic carcinoma and in 15 cases of polymorphous low-grade adenocarcinoma. For galectin-3, adenoid cystic carcinomas showed specific staining only in luminal cells, mainly in the nuclei. In the cases of polymorphous low-grade adenocarcinoma, all tumor cells revealed a positive, mostly cytoplasmic, reaction to galectin-3. Both tumors showed intense cytoplasmic/nuclear staining for -catenin in the majority of cases. Cyclin D1 immunoreactivity was not detected in 14 of the 15 polymorphous low-grade adenocarcinomas studied. In contrast, adenoid cystic carcinomas showed specific nuclear staining for cyclin D1 in 10 of 15 cases studied in more than 5% of the neoplastic cells. Cyclin D1 expression was correlated with cytoplasmic and nuclear galectin-3 expression in adenoid cystic carcinomas (p<0,05). These results suggest that in adenoid cystic carcinoma galectin-3 may play a role in cellular proliferation through cyclin D1 activation. In polymorphous low-grade adenocarcinoma gal-3 expression seems to be associated with cellular differentiation. In addition, loss of cytoplasmic expression of galectin-3 in adenoid cystic carcinomas may be related to a more aggressive behavior of these lesions. Although -catenin seems to play a role in carcinogenesis, in both lesions, it seems that it does not bind to galectin-3 for cyclin D1 stimulation.

O carcinoma ex-adenoma pleomórifoco (CXAP) é a contraparte maligna do Adenoma pleomórfico (AP), sendo sua malignização descrita em 10% dos AP. Histológicamente o CXAP apresenta grande variação morfológica vista a capacidade do componente maligno se originar de diferentes estruturas do componente misto do AP. Nota-se que grande parte dos CXAP apresentam caráter infiltrativo, metástase linfonodal e metástase tardia. Para que as células neoplásicas adquiram um fenótipo com maior capacidade infiltrava é necessário que passem por um processo de transição de um fenótipo epitelial para mesenquimal. Este processo é conhecido como Transição epitélio-mesênquima (TEM). Tal processo é visto em situações fisiológicas, tais quais, migração de células ectodérmicas durante o período embriológico, reparação e cicatrização e também em processos neoplásicos. O objetivo deste trabalho é avaliar a presença de proteínas inerentes ao processo de transição epitélio mesênquima e comparar a expressão destas proteínas com achados histopatológicos sugestivos de invasão e mestástase. A análise das proteínas E-caderina e Beta-catenina em células neoplásicas de CXAP foi realizada de forma semi-quantitativa conforme sugerido pela literatura. Os casos foram subdividos de acordo com a positividade da reação de imunohistoquímica. Onde houve ausência de células positivas o caso recebeu escore 0, casos onde houve <10% de células positivas o escore foi 1, casos onde 10- 75% de células positivas escore 2 e consequentemente 3 para casos em que >75% das células eram positivas. Tais achados foram relacionados com presença de invasão angiolinfática, perineural, metástase tardia, recorrência e metástase linfonodal. De um total de 16 casos de CXAP, o sitio mais acometido foi a parótida e 53% da nossa amostra era composta por homens, a idade média foi de 52,9 anos e a parótida foi o sitio mais acometido. A análise histopatológica demonstrou que quando havia marcação para E-caderina a mesma se dava em membrana celular. 12,5% ausência de marcação, 50% dos casos com marcação fraca 31,25% dos casos com expressão moderada e 6,25% dos casos com marcação intensa. Já para Beta-catenina um caso apresentou marcação citoplasmática e os restantes em membrana celular.18,75% ausente de marcação, 25 % com marcação fraca, 50% dos casos com marcação moderada e 6,25 dos casos com marcação intensa. A imuno-marcação estava distribuída de forma difusa tanto no front de invasão quanto no parênquima do carcinoma. Casos com maior presença de E-caderina apresentaram mais metástases linfonodais, p=0,035. Para outros critérios de invasão nenhuma relação estatística significante foi observada. Sugere-se que E-caderina e Beta-catenina não fazem parte do processo de invasão e metástase de CXAP nem são fatores relacionados a invasão dos tecidos adjacentes. / Carcinoma ex-pleomorphic adenoma (CXAP) is the malignant counterpart of pleomorphic adenoma(PA), although malignant transformation of PA is unusual occurring in 10% of the PA cases. The CXAP histologically presents an intense morphologic variation due to the ability of the malignant tissue to originate from any structure of de mixed component. A significant number of CXAPs show an infiltrative behavior, lymph node metastasis and late metastasis. The cell component must undergo a morphologic alteration changing the epithelial phenotype to a mesenchymal one. That development process is known as epithelial-mesenchymal transiction (MET). This process is seen in physiologic situations, like cell migration on embryologic ectodermal evolution, tissue repair and int neoplastic processes. The main objective of this study was to evaluate immunohistochemical expression of epithelial-mesenchymal transiction proteins, e-caderin and beta-catenin in malignant areas of CXAP and correlate with pathologic parameters that indicates migration, like perineural and angiolymphatic invasion and metastasis as suggested by the literature. Immunohistochemical analysis was performed semiquantitatively according to the scores 0 (no positive cell), 1 (<10% positive cells), 2 (10-75% of cells positive, and 3 (>75% positive cells). These results were also correlated with pathological parameters of neoplastic aggressiveness using the Fisher\'s exact test. Of the16 cases, the parotid gland was the most involved site and men were affected in 53.8 % of our sample. The mean age was 52.9 year. The histopathological analysis showed that in all cases in which e-caderin was positive, the immunoreaction was of the cell membrane 12,5% of the cases showed absent of e-caderin expression, 50% showed weak expression, 31,25% showed moderate expression and 6,25 show strong one. In the other hand, b-catenin showed cytoplasmic expression in one case, all other cases showed protein in cell membrane. 18,75 showed absent expression, 25% showed weak expression, 50% showed moderate and 6,25% showed intense one. The immunohistochemical reaction was diffuse and presented itself in invasion front as well as in the carcinoma parenchyma. Cases presenting high expression of e-caderin developed more lymph node metastasis, p=0,035. For the others invasion parameters there was no statistic summary observed. This work suggest that e-caderin and b-catenin have no relation to CXAP carcinogenesis or invasion process

A Ouabaína (OUA), esteroide cardiotônico endógeno, ao ligar-se a enzima NKA pode sinalizar modulando a atividade da Src quinase e os níveis intracelulares de Ca2+, desencadeando a ativação de diversas vias de sinalização, dentre elas a via do NF&#954;B, que uma vez ativada, é capaz de ativar outras vias de sinalização, como a via canônica da WNT. O objetivo dessa tese foi verificar os efeitos da administração intrahipocampal de OUA, em ratos, na sinalização das vias NF&#954;B, BDNF/CREB e canônica da WNT, assim como os possíveis efeitos morfológicos e funcionais. Os resultados sugerem que a OUA altera o microambiente celular favorecendo a ativação das vias propostas levando ao aumento da arborização dendrítica de neurônios do CA1 e do GD, com melhora da memória de referência espacial dos animais e piora do processo de extinção de memória de longa duração, também conhecido como flexibilidade comportamental, além de proteger os neurônios da apoptose frente a um estímulo excitotóxico. / It is well established that Ouabain (OUA), an endogenous cardiotonic steroid, can bind to NKA and trigger activation of signaling pathways dependent on Src kinase activation and intracellular Ca2+ levels oscillation, what can lead to NF&#954;B activation, and in turn, can transactivate other signaling pathways, such as the canonical WNT pathway. The aim of this thesis was to investigate the effects of intrahippocampal administration of OUA in adult rats, whether it was able to activate NF&#954;B, BDNF/CREB and the canonical WNT signaling pathways, as well as the possible morphological and functional effects of this injection. Results suggested that OUA changed the cellular microenvironment in favor to the activation of the proposed pathways leading to increased dendritic branching in CA1 and DG neurons, with spatial reference memory improvement and worsening of long-term memory extinction. Furthermore, OUA protected neurons from apoptosis stimulus triggered by excitotoxicity.

Signaling pathways are complex and function to transmit signals from the extracellular environment into the cell. Analysis of results obtained from a high throughput siRNA screen led to the identification of Membrane protein palmitoylated 3 (MPP3) and Leukocyte Tyrosine Kinase (LTK) as novel negative regulators of the Wnt pathway. MPP3 is a MAGUK family protein and domain mapping studies indicated that the Guk domain plays a role in the negative regulation of the pathway. LTK, a receptor tyrosine kinase, has several transcript variants one of which lacks the entire kinase domain (LTK∆KD). While LTK∆KD interacted with the Wnt receptor Frizzled7, the full length LTK did not, suggesting distinct modes of pathway regulation. Analysis of neuronal cells, NIE115 and Neuro2a, demonstrated LTK is expressed and that cells are Wnt3a responsive, thereby providing a neuronal model system appropriate for further studies on the mechanism and biological role of LTK as a negative regulator of the Wnt pathway

Signaling pathways are complex and function to transmit signals from the extracellular environment into the cell. Analysis of results obtained from a high throughput siRNA screen led to the identification of Membrane protein palmitoylated 3 (MPP3) and Leukocyte Tyrosine Kinase (LTK) as novel negative regulators of the Wnt pathway. MPP3 is a MAGUK family protein and domain mapping studies indicated that the Guk domain plays a role in the negative regulation of the pathway. LTK, a receptor tyrosine kinase, has several transcript variants one of which lacks the entire kinase domain (LTK∆KD). While LTK∆KD interacted with the Wnt receptor Frizzled7, the full length LTK did not, suggesting distinct modes of pathway regulation. Analysis of neuronal cells, NIE115 and Neuro2a, demonstrated LTK is expressed and that cells are Wnt3a responsive, thereby providing a neuronal model system appropriate for further studies on the mechanism and biological role of LTK as a negative regulator of the Wnt pathway

La transició Epiteli-Mesènquima es dóna durant el desenvolupament embrionari i en els estadis tardans de la progressió tumoral permetent que es produeixi la metàstasi. Aquestes transicions necessiten una repressió de l'E-Cadherina i es pot reproduir en cèl·lules en cultiu amb l'expressió ectòpica de Snail1, un repressor de l'E-Cadherina. Durant la transició produïda per Snail es produeix la ràpida activació de gens mesenquimals com Fibronectina i LEF1. L'expressió forçada d'E-Cadherina fa disminuir els nivells de RNA de Fibronectina i LEF1, indicant que en l'activació d'aquests dos gens està implicat un cofactor sensible a l'E-Cadherina. En concordança, la transcripció de Fibronectina i LEF1 és depenent de &#61538;-Catenina i NF&#61547;B. La sobreexpressió d'E-Cadherina inhibeix l'activitat transcripcional d'aquests dos factors i disminueix la seva interacció amb el promotor de Fibronectina. De manera similar a la &#61538;-Catenina, NF&#61547;B es detecta associat a l'E-Cadherina i altres components dels contactes intercel·lulars. Quan es trenquen les unions adherents, com quan es sobreexpressa Snail, la interacció E-Cadherina-NF&#61547;B disminueix i augmenta l'activitat transcripcional de NF&#61547;B i&#61472;&#61472;&#61538;-Catenina. / Epithelial to mesenchymal transitions takes place during embryo development and in the late stages of tumorigenesis allowing metastasis formation. These transitions require E-Cadherin downregulation and can be reproduced in cell culture by ectopic expression of Snail1, an E-Cadherin gene repressor. During Snail-induced transition a rapid upregulation of mesenchymal genes such as Fibronectin and LEF1 has been characterized. Forced expression of E-Cadherin strongly down-regulates Fibronectin and LEF1 RNA levels, indicating that an E-Cadherin sensitive cofactor is involved in the activation of these genes. Accordingly, transcription of Fibronectin and LEF1 was dependent on &#61538;-Catenin and NF&#61547;B. E-Cadherin over-expression downregulated the transcriptional activity of both factors and decreased their interaction to Fibronectin promoter. Similarly to &#61538;-Catenin, NF&#61547;B was detected associated to E-Cadherin and other cell adhesion components. Association of NF&#61547;B to E-Cadherin required the integrity of this complex; conditions that disrupts adherens junctions, such as Snail over-expression, decreased E-Cadherin-NF&#61547;B interaction and up-regulates NF&#61547;B and &#61538;-Catenin transcriptional activity. Therefore, &#61538;-Catenin and NF&#61547;B transcriptional activities are required for expression of the studied mesenchymal genes and these activities are inactivated by immobilizing &#61538;-Catenin and NF&#61547;B to functional E-Cadherin structures.

Proteomic techniques were used to analyze the protein expression profile of the early-stage differentiation of pig embryonic stem cells (ES cells). The pig ES cells were induced to develop to neuronal cells by all-trans retinoic acid (ATRA) in vitro by Tainan Livestock Research Institute. The ES cells were cultured with ATRA and collected at time intervals of 0, 1, 2, 4, 8 and 10 days. The cell lysates were analyzed by two-dimensional electrophoresis, and the differentially expressed proteins are identified by MALDI-TOF. Our data shows that the expression profile of pig ES cells is similar to other mammalian models but with some differences. Preliminary pig ES cells 2D database was set up. Six spots each with up or down-regulation in neurogenesis were identified by MS. These proteins may become the good markers of pig ES cells into neural cells by RA. Among those proteins, vimentin, prohibitin and annexin A10 were up-regulated, zinc finger protein 482 (ZNF482), fyn-related kinase (FRK) and annexin A1 were down-regulated during differentiation of pig ES cells to neural cells. Addtionally, we ultilized RT-PCR technique to investigate mRNA expression during neurogenesis, vimentin and prohibitin was up-regulated, anxa1(annexin A1) was slightly down-regulated, neuroD1 and neurogenin 2 were high expression on day 10, beta-catenin was high expression on day 8 to 10.

Les lésions tumorales cortico-surrénaliennes sont majoritairement des adénomes bénins et très rarement des carcinomes. Les altérations génétiques impliquées dans le développement des tumeurs cortico-surrénaliennes sporadiques, plus particulièrement au stade malin, demeurent à ce jour très peu connues. Lors de travaux récents menant à l’identification d’altérations génétiques de β-CATÉNINE nous avons constaté que plusieurs tumeurs présentaient une accumulation nucléo/cytoplasmique de la protéine β-CATÉNINE sans toutefois contenir de mutations pour ce gène. Nous avons donc émis l’hypothèse que, comme pour d’autres types de cancers, d’autres composants de la voie de signalisation Wnt/β-CATÉNINE, tel qu’AXIN2, pourrait être impliqués dans le développement des tumeurs du cortex surrénalien. De plus, plusieurs aberrations dans l’expression d’AXIN2 et de β-CATÉNINE sont associées à des tumeurs présentant de l’instabilité microsatellite dans d’autres types de cancer, notamment le cancer gastrique et colorectal. Nous avons donc étudié une cohorte de 30 adénomes, 6 carcinomes, 5 AIMAH, 3 hyperplasies ACTH-dépendante et 5 PPNAD ainsi que les lignées cellulaires de carcinomes cortico-surrénaliens humains H295R et SW13. Une étude préliminaire du statut MSI a également été réalisée sur 10 tumeurs contenant une mutation pour AXIN2 et/ou β-CATÉNINE. Nous avons trouvé des mutations d’AXIN2 dans 7% des adénomes (2/30) et 17% des carcinomes (1/6) cortico-surrénaliens. L’analyse fonctionnelle des mutations par immunohistochimie, analyse western blot et analyse de RT-PCR en temps réel a révélé une diminution de l’expression d’AXIN2 associée à cette mutation. L’analyse préliminaire MSI a démontré 1 échantillon AIMAH MSI-H, c’est-à-dire instable pour le locus BAT-25 et BAT-26 et 3 autres adénomes sécrétant de l’aldostérone instables seulement pour le locus BAT-26. Ainsi, ces travaux permirent d’identifier une nouvelle altération génétique associée au développement des tumeurs du cortex surrénalien en plus de rapporter pour la première fois la présence de MSI-H dans ce type de tumeurs. / Adrenocortical lesions are mostly benign tumors and rarely carcinomas. From now on, genetic alterations implicated in sporadic adrecocortical tumour development remains largely unknown. In our previous work leading to identification of genetic alterations in β-catenin, we observed that many tumors presented a nucleo/cytoplasmic accumulation of β-catenin protein without β-catenin mutations. Thus, we hypothesised that, as for many others cancers, others components of the Wnt/ β-catenin signalling pathway, as AXIN2, are implicated in development of adrenocortical tumors. Also, many aberrations in AXIN2 and β-catenin expression have been reported in association with microsatellite instability in other types of cancers like gastroinstestinal and colorectal cancer. We have studied 30 adenomas, 6 carcinomas, 5 AIMAH, 3 ACTH-dependant hyperplasias and 5 PPNAD as well as the human carcinoma cancer cells lines H295R and SW13. Preliminary study for MSI was also realised on 10 tumors harbouring AXIN2 and/or Β-CATENIN mutations. We have found AXIN2 mutations in 7% of adrenocortical adenomas (2/30) and 17% of adrenocortiocal carcinomas. Functional analysis of this mutation by immunohistochemical, western blot and real-time RT-PCR analysis revealed a down-regulation of AXIN2 expression associated with this mutation. Preliminary analysis of MSI results in 1 AIMAH sample MSI-H, which means instable for BAT-25 and BAT-26 locus, and 2 aldosterone adenomas were unstable for BAT-26 locus. This work identified a new genetic alteration involved in adrenocortical tumour development and report for the first time MSI-H in this type of tumor.

[Truncated abstract] In recent years a better understanding of the biology of PPAR , a nuclear transcription factor, has emerged, leading to a resurgence in targeting PPAR for chemotherapy. The family of synthetic PPAR agonists, the thiazolidinediones (TZDs), and non-steroidal anti-inflammatory drugs (NSAIDs) have been implicated in the inhibition of cell proliferation, apoptosis and cell cycle arrest of androgen-sensitive (LNCaP) and androgen-independent (PC-3 and DU145) prostate cancer cells generating much interest in their use for potential curative cancer therapies. In light of the potential use of TZDs and NSAIDs in prostate cancer prevention and their ability to induce inhibitory effects in vitro and in vivo, the first aim of this project was to undertake a comprehensive study of the effects of ciglitazone (TZD) and indomethacin (NSAID) on the androgen-independent prostate cancer cell line DU145, using standardised concentrations and time-points to compare the effects of TZDs and NSAIDs on cell proliferation, cell cycle and apoptosis. Treating the cells with either 10 µM ciglitazone or 10 µM indomethacin resulted in a time-dependent decrease in DU145 cell proliferation. The anti-proliferative effects were found to be in-part attributed to the slowing of cell progression through the G1/S-phase checkpoint of the cell cycle, and in the case of ciglitazone, apoptosis also played a role in its anti-proliferative effects in this cell line. Interestingly, although indomethacin failed to induce apoptosis, its antiproliferative effects were more potent than ciglitazone. The second aim of this project was to further investigate the underlying mechanisms responsible for the anti-proliferative effects of ciglitazone and indomethacin by evaluating their ability to modulate PPAR mRNA and protein expression, and to induce PPAR transcriptional activity. ... In addition, ligandinduced regulation of secreted frizzled related protein 4 (sFRP4) expression, a Wnt/ - catenin antagonists, was investigated. It was demonstrated that both ciglitazone and indomethacin attenuated Wnt/ -catenin signalling via the down-regulation of total - catenin levels within the cells, inhibition or slowing of the translocation of cytoplasmic -catenin into the nucleus and inhibition of cyclin–D1 expression An inverse relationship between PPAR and -catenin protein levels was also detected, suggesting that PPAR may directly bind to -catenin itself. sFRP4 expression was transiently upregulated by ciglitazone and indomethacin-treatment, suggesting that the antiproliferative effects of the ligands may be mediated in part through regulation of sFRP4 mRNA and protein levels. In summary, the anti-proliferative effects of ciglitazone and indomethacin on the androgen-independent prostate cancer cell line, DU145, described in this thesis are progressive steps in characterising the role of PPAR in prostate cancer cell proliferation. The identification of indomethacin as a more potent PPAR agonist than ciglitazone represents a novel target for the development of preventative strategies for advanced disease, and the relationship between PPAR and the Wnt/ -catenin signalling pathway provide an insight into the mechanisms involved in the anti-proliferative effects of ciglitazone and indomethacin. Further studies into this relationship would advance help identify novel preventative and curative therapeutic strategies for advanced prostate cancer.

[Truncated abstract] Ovarian cancer is currently the leading cause of death from gynaecological malignancies in women from developed countries. Serous ovarian cancer is the most prevalent type of all ovarian cancers, with the majority diagnosed in an advanced stage where treatment efficacy is reduced and patient survival is poor. Because of this fact, the development of improved detection and treatment strategies are necessary, with much research focussing on the complex molecular pathways involved in ovarian tumour growth as one potential avenue for intervention. Apoptosis, or programmed cell death, is one such area of investigation because currently successful cancer treatments induce apoptosis in tumour cells. Molecular analysis of apoptosis in both normal tissue and tumours has established a positive relationship between increased expression of secreted frizzled-related protein 4 (SFRP4) and apoptosis, however to date, very little research has focussed on the role of this gene in the ovary . . . An examination of SFRP4 and β-catenin expression in 163 primary serous ovarian carcinomas revealed high SFRP4 expression was associated with low β-catenin expression and conversely, low SFRP4 was associated with high β-catenin expression in the majority of the ovarian tumours analysed, reinforcing the inverse relationship observed in the ovarian cell lines. A positive trend was observed between cancer stage and the expression level of these proteins, with increased SFRP4 expression and reduced β-catenin expression as cancer stage increased. Additionally, patient survival revealed a trend towards increased survival among ovarian cancer patients who had tumours expressing low levels of SFRP4. Taken together, the novel findings of this study indicate that the increased expression of SFRP4 observed in a large proportion of serous ovarian cancers is a cellular response to down-regulate the level of β-catenin, and thus an attempt to maintain cellular homeostasis by counteracting the excessive proliferating signals present in these tumour cells.